Teacher Retirement System of Texas Trims Stock Position in Amgen Inc. $AMGN

Key Points

• Teacher Retirement System of Texas cut its stake in Amgen by 10.5% in Q4, selling 15,152 shares and leaving 128,599 shares valued at $42.09 million.
• Other large institutions have been adding to positions—Capital World Investors, National Bank of Canada FI, VanEck and Fisher Asset Management all increased stakes—and institutional investors now own about 76.5% of the stock.
• Amgen recently beat Q4 estimates (EPS $5.29 vs. $4.76), set FY2026 guidance of 21.60–23.00 EPS, declared a $2.52 quarterly dividend (2.9% yield), and carries a consensus analyst rating of "Hold" with a $356.62 target.

Teacher Retirement System of Texas decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 128,599 shares of the medical research company's stock after selling 15,152 shares during the quarter. Teacher Retirement System of Texas' holdings in Amgen were worth $42,092,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Capital World Investors grew its stake in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. National Bank of Canada FI raised its position in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock worth $346,076,000 after acquiring an additional 863,216 shares during the period. Van ECK Associates Corp boosted its stake in shares of Amgen by 71.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock worth $383,254,000 after acquiring an additional 567,400 shares in the last quarter. Fisher Asset Management LLC grew its position in shares of Amgen by 91.6% during the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company's stock valued at $221,607,000 after acquiring an additional 375,463 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Amgen during the 3rd quarter valued at about $101,076,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMGN has been the subject of several research analyst reports. Guggenheim upped their target price on Amgen from $347.00 to $351.00 and gave the stock a "neutral" rating in a research note on Thursday, April 9th. Leerink Partners reissued a "market perform" rating and issued a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Daiwa Securities Group lifted their target price on shares of Amgen from $370.00 to $410.00 and gave the company an "outperform" rating in a research report on Tuesday, February 10th. Finally, Canaccord Genuity Group started coverage on shares of Amgen in a research report on Monday. They set a "hold" rating and a $366.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $356.62.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Amgen Stock Up 0.8%

NASDAQ AMGN opened at $348.62 on Friday. The business has a fifty day moving average price of $361.24 and a 200 day moving average price of $338.80. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market cap of $188.14 billion, a P/E ratio of 24.50, a P/E/G ratio of 3.62 and a beta of 0.47. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm's quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 22.18 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.